Based on an analysis of 299 AML patients, mutations in spliceosome genes such as SRSF2, SF3B1, ZRSF2 and U2AF1, EZH2, BCOR and STAG2 are >95% specific for AML-MRC and can distinguish AML-MRC from de novo AML, even in the absence of an antecedent MDS diagnosis [8]. This evidence concerns the gene CD200 and myelodysplastic syndrome.